The U.S. Food and Drug Administration has approved Genentech's Susvimo (ranibizumab) 100 mg/mL for treating diabetic macular ...

Opthea Limited (ASX/NASDAQ:OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including ...

Our vision declines as we age leading to the development of various eye conditions such as presbyopia cataracts and glaucoma ...

This research team evaluated the effectiveness of switching patients to faricimab treatment by assessing their outcomes after ...

Nearly every disease has an inflammatory component, but blood tests can't pinpoint inflammation in specific organs or tissues ...

Roche’s Susvimo receives US FDA approval for the treatment of diabetic macular edema: Basel Thursday, February 6, 2025, 11:00 Hrs [IST] Roche announced that the US Food and Drug ...

Opthea Limited (NASDAQ:OPT), a biopharmaceutical company with a market capitalization of $894.5 million specializing in the ...

A sight loss organisation’s services in Scotland have been awarded a cash boost of nearly £100,000 for the next three years.

Night driving glasses claim to help you see at night when you are behind the wheel. But do they actually work, and are they ...

According to the website A Senior Connection, here are the top 10 issues that worry senior citizens the most: 1. Health Care ...